Novartis AG is considering a bid for eye-disease assets that Takeda Pharmaceutical Co. gained through its $62 billion acquisition of Shire Plc, according to people familiar with the situation.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,